ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the presentation of preclinical data from its CYPS317 program for psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting taking place May 13-15, 2026, in Chicago, Illinois.
Details of the presentations are as follows: Event: Society for Investigative Dermatology 2026 Annual Meeting Presenter: Chuo Fang, MD, Ph.D., Senior Scientist at FibroBiologics Session Date and Time: 4:30 p.m. – 6 p.m. CT on May 15, 2026 Location: Salons B, C, D; Williford – 3rd Floor
About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
